Top

Published in:

01-09-2010 | Review

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

Authors: Golo Ahlenstiel, David R. Booth, Jacob George

Published in: Journal of Gastroenterology | Issue 9/2010

Abstract

Three landmark genome-wide association studies (GWAS) published in 2009 identified the interleukin (IL) 28B gene locus as pivotal to the pathogenesis of hepatitis C virus (HCV) infection. Polymorphisms near the IL28B gene not only predicted treatment-induced and spontaneous recovery from HCV infection, but they also explained, to some extent, the difference in response rates between Caucasians and African Americans to standard therapy with pegylated interferon and ribavirin. The revelation that IL28B, an innate cytokine, plays an essential role in the pathogenesis, outcomes, and treatment responses to HCV infection has triggered a gold rush and an ever increasing number of reports on the subject are being presented at international conferences and in scientific journals. This review will summarize currently available data on the clinical impact of IL28B polymorphisms on HCV infection and the potential mechanisms for its effects. It will conclude with a discussion on how the research observations may translate into clinical practice and drug development.

Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature. 2009;461:399–401.CrossRefPubMed

Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet. 2009;41:1100–4.CrossRefPubMed

Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet. 2009;41:1105–9.CrossRefPubMed

WHO. Hepatitis C. Fact Sheet No. 164. Revised October 2000. http://www.who.int/mediacentre/factsheets/fs164/en/ (2000).

Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat. 2006;13:34–41.CrossRefPubMed

Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–9.CrossRefPubMed

Burra P. Hepatitis C. Semin Liver Dis. 2009;29:53–65.CrossRefPubMed

Australia and New Zealand Liver Transplant Registry ebSVL, G.A. Balderson. ANZLT Registry Report 2008, Brisbane, Queensland, Australia, 2008.

NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002;19:1–46.

10.

Feld JJ, Hoofnagle JH. Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature. 2005;436:967–72.CrossRefPubMed

11.

Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology. 2010;138:1338–45, 1345.e1–7.

12.

Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. IL28B polymorphism improves viral kinetics and is the strongest pre-treatment predictor of SVR in HCV-1 patients. Gastroenterology. 2010;in press.

13.

McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an interleukin-28B gene variant and a sustained response to pegylated interferon and ribavirin. Gastroenterology. 2010;138:2307–14.CrossRefPubMed

14.

Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. IL28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology. 2010;52:33–7.

15.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in HCV core region and genetic variation near IL28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology. 2010;in press.

16.

Rallon NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS. 2010;24:F23–9.CrossRefPubMed

17.

Nischalke HD, Vogel M, Michalk M, Mauss S, Baumgarten A, Naumann U, et al. Genetic variation in IL28B rs 12979860 and response to HCV-specific treatment in HIV/HIV co-infected patients. J Hepatol. 2010;52:S453.CrossRef

18.

Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically hepatitis C virus infected patients. J Hepatol. 2010;52:S449.

19.

Li JH, Qian Lao X, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology. 2010;51:1904–11.PubMed

20.

Eurich D, Boas-Knoop S, Ruehl M, Schulz M, Carrillo ED, Bahra M, et al. IL-28B gene polymorphism influences histological and biochemical severity of graft hepatitis after liver transplantation for HCV-induced liver disease. J Hepatol. 2010;52:S450.CrossRef

21.

Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009;461:798–801.CrossRefPubMed

22.

Mangia A, Santoro R, Mottola L, Piazzolla V, Bacca D, Sarli R, et al. IL28B C/C polymorphism is predictive of spontaneous HCV RNA clearance in patients with thalassemia major. J Hepatol. 2010;52:S452.CrossRef

23.

Matsuura K, Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Izumi N, et al. Identification of genetic variants of the IL28B associated with spontaneous clearance of hepatitis C virus in Japanese population. J Hepatol. 2010;52:S452.CrossRef

24.

Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol. 2009;86:23–32.CrossRefPubMed

25.

Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.CrossRefPubMed

26.

Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol. 2003;4:63–8.CrossRefPubMed

27.

Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol. 2005;174:1932–7.PubMed

28.

Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun. 2009;10:702–14.CrossRefPubMed

29.

Goodbourn S, Didcock L, Randall RE. Interferons: cell signalling, immune modulation, antiviral response and virus countermeasures. J Gen Virol. 2000;81:2341–64.PubMed

30.

Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. J Biol Chem. 2004;279:32269–74.CrossRefPubMed

31.

Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology. 2006;44:896–906.CrossRefPubMed

32.

Maher SG, Sheikh F, Scarzello AJ, Romero-Weaver AL, Baker DP, Donnelly RP, et al. IFNalpha and IFNlambda differ in their antiproliferative effects and duration of JAK/STAT signaling activity. Cancer Biol Ther. 2008;7:1109–15.PubMed

33.

Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology. 2006;131:1887–98.CrossRefPubMed

34.

Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol. 2005;79:3851–4.CrossRefPubMed

35.

Mihm S, Frese M, Meier V, Wietzke-Braun P, Scharf JG, Bartenschlager R, et al. Interferon type I gene expression in chronic hepatitis C. Lab Invest. 2004;84:1148–59.CrossRefPubMed

36.

Honda M, Sakai A, Yamashita T, Nakamoto E, Sakai Y, Yamashita T, et al. Hepatic ISG expression is associated with genetic variation in IL28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology. 2010;in press.

37.

Abe H, Hayes CN, Ochi H, Maekawa T, Tsuge M, Miki D, et al. Common variation of IL28 affects intrahepatic expression of interferon stimulated genesis and correlates with effect of peg-interferon and ribavirin combination therapy. J Hepatol. 2010;52:S449.

38.

Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology. 2005;128:1437–44.CrossRefPubMed

39.

Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology. 2007;46:1548–63.CrossRefPubMed

40.

Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB, et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol. 2008;180:2474–85.PubMed

41.

Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med. 2006;12:1023–6.CrossRefPubMed

42.

Freeman JA, Zhang T, Holdren MS, Hausman DF. Peg-interferon lambda (PEG-IL-29): translation of in vitro preclinical data to clinical results. J Hepatol. 2008;48:S294.CrossRef

43.

Dodds MG, Hausman DF, Miller DM. Viral kinetic modeling during treatment with interferon lambda-1a in genotype 1 chronic hepatitis C patients. J Hepatol. 2009;50:S342.CrossRef

44.

Shiffman M, Lawitz E, Zaman A, Vierling J, Yoffe B, Freeman J, et al. PEG-IFN-l: antiviral activity and safety profile in a 4-week phase 1b study in relapsed genotype 1 hepatitis C infection. J Hepatol. 2009;50:S237.CrossRef

Title: IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice
Authors: Golo Ahlenstiel
David R. Booth
Jacob George
Publication date: 01-09-2010
Publisher: Springer Japan
Published in: Journal of Gastroenterology / Issue 9/2010
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI: https://doi.org/10.1007/s00535-010-0287-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2010

Development and validation of a modified fecal incontinence quality of life scale for Japanese patients after intersphincteric resection for very low rectal cancer

Regulatory T cells are associated with post-cryoablation prognosis in patients with hepatitis B virus-related hepatocellular carcinoma

Adiponectin receptors are downregulated in human gastric cancer

Erratum to: A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose–response of tolvaptan in patients with decompensated liver cirrhosis

Novel endoscopic activity index is useful for choosing treatment in severe active ulcerative colitis patients

Inflammatory bowel disease in children: epidemiological analysis of the nationwide IBD registry in Japan

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page